Long non-coding RNAs BACE1-AS and BC200 in multiple sclerosis and their relation to cognitive function: A gene expression analysis

Kamal, Ahmed; Swellam, Menha Mahmoud; Shalaby, Nevin; Darwish, Marwa K.; Elnahrery, Islam M

doi:10.1016/j.brainres.2023.148424

Cited by 7 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PPMS group had the highest expression of BC200 in both cohorts of MS. It was also found that there is a strong positive correlation between BACE1-AS and BC200, enforcing their role as molecular regulatory actors of MS [147].…”

Section: Lncrnas-biomarkersmentioning

confidence: 82%

Multiple Sclerosis: Roles of miRNA, lcnRNA, and circRNA and Their Implications in Cellular Pathways

Cipriano,

Schepici,

Mazzon

et al. 2024

IJMS

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a degenerative condition characterized by axonal damage and demyelination induced by autoreactive immune cells that occur in the Central Nervous System (CNS). The interaction between epigenetic changes and genetic factors can be widely involved in the onset, development, and progression of the disease. Although numerous efforts were made to discover new therapies able to prevent and improve the course of MS, definitive curative treatments have not been found yet. However, in recent years, it has been reported that non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long ncRNAs (lncRNAs), and circular RNAs (circRNAs), acting as gene expression regulators, could be used as potential therapeutic targets or biomarkers to diagnose and fight MS. In this review, we discussed the role of miRNAs, lncRNAs, and circRNAs, as well as their expression level changes and signaling pathways that are related to preclinical and human MS studies. Hence, the investigation of ncRNAs could be important to provide additional information regarding MS pathogenesis as well as promote the discovery of new therapeutic strategies or biomarkers.

show abstract

Section: Lncrnas-biomarkersmentioning

confidence: 82%

Multiple Sclerosis: Roles of miRNA, lcnRNA, and circRNA and Their Implications in Cellular Pathways

Cipriano,

Schepici,

Mazzon

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Subsequent careful screening of abstracts led to the exclusion of 295 articles. Final inclusion criteria—excluding animal cell experiments, non-blood sample studies, data extraction issues, reviews, and comments—resulted in 13 studies ( Gharesouran et al, 2019b ; Sayad et al, 2019 ; Shaker et al, 2019 ; Ghaiad et al, 2020 ; Senousy et al, 2020 ; Safa et al, 2021 ; Soltanmoradi et al, 2021 ; Akbari et al, 2022 ; Amiri et al, 2022 ; Attia et al, 2023 ; Ghafouri-Fard et al, 2023 ; Kamal et al, 2023 ; Kortam et al, 2023 ) qualifying for the meta-analysis. This process is detailed in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

Diagnostic efficacy of long non-coding RNAs in multiple sclerosis: a systematic review and meta-analysis

Wang,

Zhang

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

BackgroundCurrently, an increasing body of research suggests that blood-based long non-coding RNAs (lncRNAs) could serve as biomarkers for diagnosing multiple sclerosis (MS). This meta-analysis evaluates the diagnostic capabilities of selected lncRNAs in distinguishing individuals with MS from healthy controls and in differentiating between the relapsing and remitting phases of the disease.MethodsWe conducted comprehensive searches across seven databases in both Chinese and English to identify relevant studies, applying stringent inclusion and exclusion criteria. The quality of the selected references was rigorously assessed using the QUADAS-2 tool. The analysis involved calculating summarized sensitivity (SSEN), specificity (SSPE), positive likelihood ratio (SPLR), negative likelihood ratio (SNLR), and diagnostic odds ratio (DOR) with 95% confidence intervals (CIs). Accuracy was assessed using summary receiver operating characteristic (SROC) curves.ResultsThirteen high-quality studies were selected for inclusion in the meta-analysis. Our meta-analysis assessed the combined diagnostic performance of lncRNAs in distinguishing MS patients from healthy controls. We found a SSEN of 0.81 (95% CI: 0.74–0.87), SSPE of 0.84 (95% CI: 0.78–0.89), SPLR of 5.14 (95% CI: 3.63–7.28), SNLR of 0.22 (95% CI: 0.16–0.31), and DOR of 23.17 (95% CI: 14.07–38.17), with an AUC of 0.90 (95% CI: 0.87–0.92). For differentiating between relapsing and remitting MS, the results showed a SSEN of 0.79 (95% CI: 0.71–0.85), SSPE of 0.76 (95% CI: 0.64–0.85), SPLR of 3.34 (95% CI: 2.09–5.33), SNLR of 0.28 (95% CI: 0.19–0.40), and DOR of 12.09 (95% CI: 5.70–25.68), with an AUC of 0.84 (95% CI: 0.81–0.87).ConclusionThis analysis underscores the significant role of lncRNAs as biomarkers in MS diagnosis and differentiation between its relapsing and remitting forms.

show abstract

“…Further lncRNA targets of interest include activity-dependent transported Adeptr [171], brain cytoplasmic BC200 [172][173][174][175], BACE1-AS (antisense relative to β-secretase 1 gene) [176][177][178], and Carip [179]. In addition, other types of ncRNAs (miRNAs, piRNAs, lncRNAs, circRNAs) are dysregulated in AD and related dementias with first evidence for therapeutic potential [161] (Figure 7).…”

Section: Primate/human-specific Ncrnas In Neural/neuroimmune Cells An...mentioning

confidence: 99%

Exploration of the Noncoding Genome for Human-Specific Therapeutic Targets—Recent Insights at Molecular and Cellular Level

Poller,

Sahoo,

Hajjar

et al. 2023

Cells

View full text Add to dashboard Cite

While it is well known that 98–99% of the human genome does not encode proteins, but are nevertheless transcriptionally active and give rise to a broad spectrum of noncoding RNAs [ncRNAs] with complex regulatory and structural functions, specific functions have so far been assigned to only a tiny fraction of all known transcripts. On the other hand, the striking observation of an overwhelmingly growing fraction of ncRNAs, in contrast to an only modest increase in the number of protein-coding genes, during evolution from simple organisms to humans, strongly suggests critical but so far essentially unexplored roles of the noncoding genome for human health and disease pathogenesis. Research into the vast realm of the noncoding genome during the past decades thus lead to a profoundly enhanced appreciation of the multi-level complexity of the human genome. Here, we address a few of the many huge remaining knowledge gaps and consider some newly emerging questions and concepts of research. We attempt to provide an up-to-date assessment of recent insights obtained by molecular and cell biological methods, and by the application of systems biology approaches. Specifically, we discuss current data regarding two topics of high current interest: (1) By which mechanisms could evolutionary recent ncRNAs with critical regulatory functions in a broad spectrum of cell types (neural, immune, cardiovascular) constitute novel therapeutic targets in human diseases? (2) Since noncoding genome evolution is causally linked to brain evolution, and given the profound interactions between brain and immune system, could human-specific brain-expressed ncRNAs play a direct or indirect (immune-mediated) role in human diseases? Synergistic with remarkable recent progress regarding delivery, efficacy, and safety of nucleic acid-based therapies, the ongoing large-scale exploration of the noncoding genome for human-specific therapeutic targets is encouraging to proceed with the development and clinical evaluation of novel therapeutic pathways suggested by these research fields.

show abstract

Long non-coding RNAs BACE1-AS and BC200 in multiple sclerosis and their relation to cognitive function: A gene expression analysis

Cited by 7 publications

References 45 publications

Multiple Sclerosis: Roles of miRNA, lcnRNA, and circRNA and Their Implications in Cellular Pathways

Multiple Sclerosis: Roles of miRNA, lcnRNA, and circRNA and Their Implications in Cellular Pathways

Diagnostic efficacy of long non-coding RNAs in multiple sclerosis: a systematic review and meta-analysis

Exploration of the Noncoding Genome for Human-Specific Therapeutic Targets—Recent Insights at Molecular and Cellular Level

Contact Info

Product

Resources

About